Prescient Therapeutics LimitedASX: PTX

PTX-200 High Overall Response in Ph2a Breast Cancer trial

Dec 23, 2019 at 3:25 AM UTC · Issued by Prescient Therapeutics Limited

Prescient Therapeutics Ltd has released a press release.

View Attachment